New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 4, 2013
08:41 EDTARAY, AUO, FL, SONC, LLY, FINL, FOLD, LULUOn The Fly: Pre-market Movers
HIGHER AFTER GUIDANCE: Eli Lilly (LLY), up 1.7%... ALSO HIGHER: Amicus Theraputics (FOLD), up 8.5% after announcing results from Phase 2 study... AU Optronics (AUO), up 4.7% after DigiTimes said company asked to join Amazon supply chain... LOWER AFTER EARNINGS/GUIDANCE: Finish Line (FINL), down 7%... Sonic (SONC), down 5%... Accuray (ARAY), down 25.5%... ALSO LOWER: Foot Locker (FL), down 2% after disappointing results, guidance of peer Finish Line... lululemon (LULU), down 3.9% after downgrade to Neutral at Credit Suisse.
News For FINL;FL;LULU;LLY;AUO;FOLD;SONC;ARAY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
November 17, 2014
06:05 EDTLULUStocks with implied volatility above IV index mean; GME LULU
Subscribe for More Information
November 16, 2014
14:53 EDTFOLDAmicus announces positive data from Fabry monotherapy study
Amicus Therapeutics announced additional positive data on important secondary endpoints from its second Phase 3 study of the oral small molecule chaperone migalastat HCl for Fabry disease. In a poster1 at the American Society of Nephrology Kidney Week 2014, results were presented from Fabry patients with amenable mutations in Study 012 who switched from standard of care enzyme replacement therapy, ERT, to migalastat as their only therapy for Fabry disease. Data from the Fabry Registry indicate that the leading cause of death in patients is from cardiac complications2. In Study 012, patients who switched from ERT to migalastat showed a statistically significant decrease from baseline to month 18 in left ventricular mass index-LVMi. LVMi is a measure of cardiac hypertrophy, an increase in the size of the heart that has been associated with an increased risk of cardiac events in Fabry patients."Cardiac disease represents a major cause of morbidity and mortality in Fabry patients that is not adequately addressed with currently available treatment," said Professor Ales Linhart, MD, PhD, a leading expert in the cardiac manifestations of Fabry disease from Charles University of Prague. "The data showing further regression of left ventricular mass in patients switched from ERT to migalastat in this study are very promising since in other cardiac conditions a reduction of cardiac mass typically translates to significant improvements in long term outcomes."
November 14, 2014
14:53 EDTLLYCVS Express Scripts implementing drug price controls, says Cleveland Research
Cleveland Research believes that CVS (CVS) and Express scripts are implementing rebates and price controls on drug. The firm expects the companies to increase their focus on controlling durg prices next year, and adds that they have already itnroduced prior authorization criteria for hepatitis drug. Publicly traded drug companies include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Makers of hepatits c drugs include AbbVie (ABBV) and Gilead (GILD),
10:00 EDTLULUOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:16 EDTLULUOn The Fly: Pre-market Movers
Subscribe for More Information
09:03 EDTLULUlululemon downgraded at Sterne Agee
As noted earlier, Sterne Agee downgraded lululemon to Neutral from Buy. The firm believes that the company's brand has been damaged, causing many customers to leave, while its competition has become stronger. Target $39.
08:54 EDTLULUlululemon down 2% to $44.14 in pre-market following Sterne Agee downgrade
Subscribe for More Information
06:30 EDTLULUlululemon downgraded to Underperform from Neutral at Sterne Agee
Subscribe for More Information
November 13, 2014
13:32 EDTLLYLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
13:29 EDTLLYLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
13:26 EDTLLYLeerink biotech analysts hold an analyst/industry conference call
Biotech Analysts provide a preview of items being discussed at the upcoming 56th Annual Meeting of ASH including Leukemia/MDS on an Analyst/Industry conference call to be held on November 20 at 10 am.
06:04 EDTLULUStocks with implied volatility above IV index mean; GME LULU
Subscribe for More Information
November 12, 2014
13:31 EDTLULULululemon Athletica volatility elevated as shares trend higher
Subscribe for More Information
08:12 EDTFOLDSeeThruEquity to hold a conference
Subscribe for More Information
November 11, 2014
16:14 EDTLLYLeerink biotech analysts hold an analyst/industry conference call
Biotech Analysts provide a preview of items being discussed at the upcoming 56th Annual Meeting of ASH including JAK inhibitors, novel Jakafi combinations for Myelofibrosis and developing compounds on an Analyst/Industry conference call to be held on November 17 at 10 am.
07:49 EDTFINLBofA/Merrill retail and consumer analysts hold analyst/industry conference call
Subscribe for More Information
November 10, 2014
15:54 EDTFOLDAmerican Society of Nephrology to hold a conference
Subscribe for More Information
09:46 EDTLULUBB&T remains positive on lululemon following channel checks
BB&T said it remains positive on lululemon following recent channel checks. The firm continues to expect lululemon's results to improve as the company improved product assortment and laps 2013 PR stumbles. BB&T views the hire of Duke Stump as EVP of Community and Brand as a a positive and views the controversy over the donation to the Dalai Lama Center as overblown. Shares are Buy rated with a $50 price target.
07:22 EDTLULUU.S. Retail Softlines sector downgraded to Negative at Barclays
Subscribe for More Information
05:48 EDTFINL, LULUU.S. Retail Softlines industry cut to Negative at Barclays
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use